Cargando…

Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients

This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizushige, Tomoko, Kobori, Hiroyuki, Hitomi, Hirofumi, Nishijima, Yoko, Tomoda, Fumihiro, Morimoto, Satoshi, Kohno, Masakazu, Nishiyama, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133801/
https://www.ncbi.nlm.nih.gov/pubmed/27801805
http://dx.doi.org/10.3390/ijms17111800
_version_ 1782471341407993856
author Mizushige, Tomoko
Kobori, Hiroyuki
Hitomi, Hirofumi
Nishijima, Yoko
Tomoda, Fumihiro
Morimoto, Satoshi
Kohno, Masakazu
Nishiyama, Akira
author_facet Mizushige, Tomoko
Kobori, Hiroyuki
Hitomi, Hirofumi
Nishijima, Yoko
Tomoda, Fumihiro
Morimoto, Satoshi
Kohno, Masakazu
Nishiyama, Akira
author_sort Mizushige, Tomoko
collection PubMed
description This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<−50%) and non-responders (≥−50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H, n = 16) and those with lower values, Group H showed significantly decreased urinary albumin (p < 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome.
format Online
Article
Text
id pubmed-5133801
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51338012016-12-12 Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients Mizushige, Tomoko Kobori, Hiroyuki Hitomi, Hirofumi Nishijima, Yoko Tomoda, Fumihiro Morimoto, Satoshi Kohno, Masakazu Nishiyama, Akira Int J Mol Sci Article This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<−50%) and non-responders (≥−50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H, n = 16) and those with lower values, Group H showed significantly decreased urinary albumin (p < 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. MDPI 2016-10-27 /pmc/articles/PMC5133801/ /pubmed/27801805 http://dx.doi.org/10.3390/ijms17111800 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mizushige, Tomoko
Kobori, Hiroyuki
Hitomi, Hirofumi
Nishijima, Yoko
Tomoda, Fumihiro
Morimoto, Satoshi
Kohno, Masakazu
Nishiyama, Akira
Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
title Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
title_full Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
title_fullStr Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
title_full_unstemmed Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
title_short Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
title_sort urinary angiotensinogen could be a prognostic marker of the renoprotection of olmesartan in metabolic syndrome patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133801/
https://www.ncbi.nlm.nih.gov/pubmed/27801805
http://dx.doi.org/10.3390/ijms17111800
work_keys_str_mv AT mizushigetomoko urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT koborihiroyuki urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT hitomihirofumi urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT nishijimayoko urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT tomodafumihiro urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT morimotosatoshi urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT kohnomasakazu urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients
AT nishiyamaakira urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients